{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:11:53Z","timestamp":1779275513795,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006942","name":"Medical University of South Carolina","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006942","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Microsatellite instability (MSI) is an established molecular biomarker in colorectal cancer (CRC). However, its stage-specific prognostic value and treatment-modifying role in colon cancer remain incompletely defined, particularly across contemporary multimodality treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using the National Cancer Database, including patients aged\u2009\u2265\u200920 years diagnosed with colon cancer between 2004 and 2020 with documented tumor stage and MSI status. MSI was categorized as microsatellite stable (MSS), MSI-low (MSI-L), or MSI-high (MSI-H). Multivariable Cox proportional hazards regression models were used to evaluate the association between MSI status and overall survival (OS), stratified by disease stage and treatment combinations. Patients who died within 90 days of diagnosis were excluded to minimize immortal-time bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 129,484 patients met inclusion criteria. MSI-H tumors comprised 16.8% of cases. The prognostic impact of MSI status varied by stage. MSI-H was not associated with OS in stage 0\u2013I disease but conferred a significant survival advantage in stage II (HR 0.86,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), stage III (HR 0.71,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), and stage IV disease (HR 0.65,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). MSI-L tumors demonstrated no consistent survival benefit, with a modest association observed only in stage IV (HR 0.89,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.015). Treatment-stratified analyses revealed that in stage II disease, MSI-H was associated with improved survival only among patients treated with surgery alone (HR 0.83,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). In contrast, MSI-H tumors demonstrated substantial survival benefit across multiple treatment pathways in stage III and IV disease, including surgery plus chemotherapy (stage III HR 0.72; stage IV HR 0.70) and immunotherapy-containing regimens (stage III HR 0.28; stage IV HR 0.47; all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MSI status demonstrates a stage-dependent role in colon cancer, serving as a prognostic biomarker in early-stage disease and a predictive marker for immunotherapy-associated survival benefit in advanced stages.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12029-026-01493-z","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:56:45Z","timestamp":1779271005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic and Treatment-Associated Survival Effects of Microsatellite Instability Across Disease Stages in Colon Cancer: An NCDB Analysis"],"prefix":"10.1007","volume":"57","author":[{"given":"Mohyeddine","family":"El Sayed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sassine","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"Chaccour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melhem El","family":"Harati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"3","key":"1493_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"1493_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.currproblcancer.2018.06.010","volume":"42","author":"R Gupta","year":"2018","unstructured":"Gupta R, Sinha S, Paul RN. The impact of microsatellite stability status in colorectal cancer. Curr Probl Cancer. 2018;42(6):548\u201359.","journal-title":"Curr Probl Cancer"},{"issue":"6","key":"1493_CR3","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1158\/1078-0432.CCR-11-1469","volume":"18","author":"FA Sinicrope","year":"2012","unstructured":"Sinicrope FA, Sargent DJ. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res. 2012;18(6):1506\u201312.","journal-title":"Clin Cancer Res"},{"issue":"22","key":"1493_CR4","first-page":"5248","volume":"58","author":"CR Boland","year":"1998","unstructured":"Boland CR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58(22):5248\u201357.","journal-title":"Cancer Res"},{"issue":"6","key":"1493_CR5","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471\u20134.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"1493_CR6","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s00384-021-03874-1","volume":"36","author":"JWT Toh","year":"2021","unstructured":"Toh JWT, et al. Rate of dissemination and prognosis in early and advanced stage colorectal cancer based on microsatellite instability status: systematic review and meta-analysis. Int J Colorectal Dis. 2021;36(8):1573\u201396.","journal-title":"Int J Colorectal Dis"},{"issue":"15","key":"1493_CR7","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1016\/j.ejca.2010.05.009","volume":"46","author":"C Guastadisegni","year":"2010","unstructured":"Guastadisegni C, et al. Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer. 2010;46(15):2788\u201398.","journal-title":"Eur J Cancer"},{"issue":"5","key":"1493_CR8","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.7150\/ijbs.88779","volume":"20","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, et al. Impact of KRAS mutation on the tumor microenvironment in colorectal cancer. Int J Biol Sci. 2024;20(5):1947\u201364.","journal-title":"Int J Biol Sci"},{"issue":"3","key":"1493_CR9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.surg.2021.10.043","volume":"171","author":"CG Tran","year":"2022","unstructured":"Tran CG, et al. The impact of KRAS mutation, microsatellite instability, and tumor laterality on the prognosis of nonmetastatic colon cancer. Surgery. 2022;171(3):657\u201365.","journal-title":"Surgery"},{"issue":"1","key":"1493_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4103\/jcrt.jcrt_1560_22","volume":"20","author":"T Gulsen","year":"2024","unstructured":"Gulsen T, et al. Clinicopathological outcomes of microsatellite instability in colorectal cancer. J Cancer Res Ther. 2024;20(1):103\u201311.","journal-title":"J Cancer Res Ther"},{"issue":"6","key":"1493_CR11","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1053\/j.gastro.2009.12.064","volume":"138","author":"CR Boland","year":"2010","unstructured":"Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138(6):2073\u201387. e3.","journal-title":"Gastroenterology"},{"issue":"2","key":"1493_CR12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/jso.25798","volume":"121","author":"I Gkekas","year":"2020","unstructured":"Gkekas I, et al. Mismatch repair status predicts survival after adjuvant treatment in stage II colon cancer patients. J Surg Oncol. 2020;121(2):392\u2013401.","journal-title":"J Surg Oncol"},{"issue":"26","key":"1493_CR13","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509\u201320.","journal-title":"N Engl J Med"},{"key":"1493_CR14","unstructured":"Database NC. About the Nartional Cancer Database. 2024; Available from: www.facs.org\/quality-programs\/cancer\/ncdb\/about"},{"issue":"3","key":"1493_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4166\/kjg.2019.73.3.159","volume":"73","author":"SA Han","year":"2019","unstructured":"Han SA, et al. The Clinical Significance of Microsatellite Instability in Patients with Right-sided Colorectal Cancer. Korean J Gastroenterol. 2019;73(3):159\u201366.","journal-title":"Korean J Gastroenterol"},{"key":"1493_CR16","doi-asserted-by":"publisher","first-page":"e2200179","DOI":"10.1200\/PO.22.00179","volume":"7","author":"C Gutierrez","year":"2023","unstructured":"Gutierrez C, et al. The Prevalence and Prognosis of Microsatellite Instability-High\/Mismatch Repair-Deficient Colorectal Adenocarcinomas in the United States. JCO Precis Oncol. 2023;7:e2200179.","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"1493_CR17","first-page":"735","volume":"16","author":"F Battaglin","year":"2018","unstructured":"Battaglin F, et al. Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. Clin Adv Hematol Oncol. 2018;16(11):735\u201345.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"50","key":"1493_CR18","doi-asserted-by":"publisher","first-page":"e2260","DOI":"10.1097\/MD.0000000000002260","volume":"94","author":"SY Lee","year":"2015","unstructured":"Lee SY, et al. Low-Level Microsatellite Instability as a Potential Prognostic Factor in Sporadic Colorectal Cancer. Med (Baltim). 2015;94(50):e2260.","journal-title":"Med (Baltim)"},{"issue":"1","key":"1493_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00384-023-04480-z","volume":"38","author":"P Rantanen","year":"2023","unstructured":"Rantanen P, et al. The prognostic significance of microsatellite instability in colorectal cancer: a Swedish multi-center study. Int J Colorectal Dis. 2023;38(1):197.","journal-title":"Int J Colorectal Dis"},{"issue":"16","key":"1493_CR20","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.2217\/cer-2021-0013","volume":"10","author":"F Baidoun","year":"2021","unstructured":"Baidoun F, Saad AM, Abdel-Rahman O. Prognostic and predictive value of microsatellite instability status among patients with colorectal cancer. J Comp Eff Res. 2021;10(16):1197\u2013214.","journal-title":"J Comp Eff Res"},{"issue":"9","key":"1493_CR21","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.7150\/jca.50285","volume":"13","author":"YC Yao","year":"2022","unstructured":"Yao YC, et al. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study. J Cancer. 2022;13(9):2912\u201321.","journal-title":"J Cancer"},{"key":"1493_CR22","doi-asserted-by":"publisher","first-page":"1278398","DOI":"10.3389\/fonc.2023.1278398","volume":"13","author":"G Tong","year":"2023","unstructured":"Tong G, et al. Correlation between mismatch repair statuses and the prognosis of stage I-IV colorectal cancer. Front Oncol. 2023;13:1278398.","journal-title":"Front Oncol"},{"issue":"3","key":"1493_CR23","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.2005.01.086","volume":"23","author":"S Popat","year":"2005","unstructured":"Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3):609\u201318.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1493_CR24","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.ejca.2011.10.005","volume":"48","author":"SP Hong","year":"2012","unstructured":"Hong SP, et al. The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer. Eur J Cancer. 2012;48(8):1235\u201343.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1493_CR25","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/his.14710","volume":"81","author":"M Swets","year":"2022","unstructured":"Swets M, et al. Microsatellite instability in rectal cancer: what does it mean? A study of two randomized trials and a systematic review of the literature. Histopathology. 2022;81(3):352\u201362.","journal-title":"Histopathology"},{"issue":"4","key":"1493_CR26","first-page":"e679","volume":"17","author":"CR Oh","year":"2018","unstructured":"Oh CR, et al. Prognostic Value of the Microsatellite Instability Status in Patients With Stage II\/III Rectal Cancer Following Upfront Surgery. Clin Colorectal Cancer. 2018;17(4):e679\u201385.","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"1493_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00384-011-1341-2","volume":"27","author":"CC Lin","year":"2012","unstructured":"Lin CC, et al. Clinicopathologic features and prognostic analysis of MSI-high colon cancer. Int J Colorectal Dis. 2012;27(3):277\u201386.","journal-title":"Int J Colorectal Dis"},{"issue":"21","key":"1493_CR28","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/jnci\/djs427","volume":"104","author":"AD Roth","year":"2012","unstructured":"Roth AD, et al. Integrated analysis of molecular and clinical prognostic factors in stage II\/III colon cancer. J Natl Cancer Inst. 2012;104(21):1635\u201346.","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"1493_CR29","doi-asserted-by":"publisher","first-page":"702","DOI":"10.21037\/atm-22-2803","volume":"10","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, et al. Prognostic impact of high-risk factors and KRAS mutation in patients with stage II deficient mismatch repair colon cancer: a retrospective cohort study. Ann Transl Med. 2022;10(12):702.","journal-title":"Ann Transl Med"},{"key":"1493_CR30","doi-asserted-by":"publisher","first-page":"853545","DOI":"10.3389\/fonc.2022.853545","volume":"12","author":"KE Hestetun","year":"2022","unstructured":"Hestetun KE, et al. Stage-dependent prognostic shift in mismatch repair-deficient tumors: Assessing patient outcomes in stage II and III colon cancer. Front Oncol. 2022;12:853545.","journal-title":"Front Oncol"},{"issue":"2","key":"1493_CR31","doi-asserted-by":"publisher","first-page":"681","DOI":"10.21037\/jgo-23-809","volume":"15","author":"N Taflin","year":"2024","unstructured":"Taflin N, et al. Survival in metastatic microsatellite-stable colorectal cancer correlated with tumor mutation burden and mutations identified by next-generation sequencing. J Gastrointest Oncol. 2024;15(2):681\u20138.","journal-title":"J Gastrointest Oncol"},{"issue":"20","key":"1493_CR32","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","volume":"20","author":"S Venderbosch","year":"2014","unstructured":"Venderbosch S, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20(20):5322\u201330.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1493_CR33","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1002\/cam4.2205","volume":"8","author":"KO Aasebo","year":"2019","unstructured":"Aasebo KO, et al. Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients. Cancer Med. 2019;8(7):3623\u201335.","journal-title":"Cancer Med"},{"key":"1493_CR34","unstructured":"Network NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Colon Version 5.2025. National Comphrensive Cancer Network; 2025."},{"issue":"7","key":"1493_CR35","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/COC.0000000000000554","volume":"42","author":"JL Koenig","year":"2019","unstructured":"Koenig JL, et al. Microsatellite Instability and Adjuvant Chemotherapy in Stage II Colon Cancer. Am J Clin Oncol. 2019;42(7):573\u201380.","journal-title":"Am J Clin Oncol"},{"issue":"10","key":"1493_CR36","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1016\/j.ejca.2009.04.018","volume":"45","author":"G Des Guetz","year":"2009","unstructured":"Des Guetz G, et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer. 2009;45(10):1890\u20136.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1493_CR37","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12885-024-11821-w","volume":"24","author":"L Liao","year":"2024","unstructured":"Liao L, et al. The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study. BMC Cancer. 2024;24(1):164.","journal-title":"BMC Cancer"},{"issue":"3","key":"1493_CR38","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1056\/NEJMoa022289","volume":"349","author":"CM Ribic","year":"2003","unstructured":"Ribic CM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247\u201357.","journal-title":"N Engl J Med"},{"issue":"8","key":"1493_CR39","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1200\/JCO.21.02538","volume":"40","author":"NN Baxter","year":"2022","unstructured":"Baxter NN, et al. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. J Clin Oncol. 2022;40(8):892\u2013910.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1493_CR40","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1158\/0008-5472.CAN-18-2991","volume":"79","author":"GV Schiappacasse Cocio","year":"2019","unstructured":"Schiappacasse Cocio GV, Schiappacasse ED. Is Adjuvant Chemotherapy Efficient in Colon Cancer with High Microsatellite Instability? A Look Towards the Future. Cancer Res. 2019;79(3):441\u20134.","journal-title":"Cancer Res"},{"issue":"17suppl","key":"1493_CR41","first-page":"LBA1","volume":"43","author":"FA Sinicrope","year":"2025","unstructured":"Sinicrope FA, et al. Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC). J Clin Oncol. 2025;43(17suppl):LBA1\u20131.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"1493_CR42","doi-asserted-by":"publisher","first-page":"e15595","DOI":"10.1200\/JCO.2023.41.16_suppl.e15595","volume":"41","author":"F Iachetta","year":"2023","unstructured":"Iachetta F, et al. Efficacy of immunotherapy in MSI metastatic colorectal cancer patients: A Real-World Italian multicentric retrospective study (Colon-MSI Study). J Clin Oncol. 2023;41(16suppl):e15595\u201315595.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1493_CR43","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.2217\/fon-2021-1633","volume":"18","author":"H Jin","year":"2022","unstructured":"Jin H, et al. Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, MSI-high or MMR-deficient CRC. Future Oncol. 2022;18(17):2155\u201371.","journal-title":"Future Oncol"},{"issue":"2","key":"1493_CR44","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S0002-9440(10)64020-5","volume":"158","author":"JR Jass","year":"2001","unstructured":"Jass JR, Young J, Leggett BA. Biological significance of microsatellite instability-low (MSI-L) status in colorectal tumors. Am J Pathol. 2001;158(2):779\u201381.","journal-title":"Am J Pathol"},{"issue":"1","key":"1493_CR45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/path.1071","volume":"197","author":"I Tomlinson","year":"2002","unstructured":"Tomlinson I, et al. Does MSI-low exist? J Pathol. 2002;197(1):6\u201313.","journal-title":"J Pathol"},{"issue":"4\u20135","key":"1493_CR46","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1155\/2004\/368680","volume":"20","author":"TM Pawlik","year":"2004","unstructured":"Pawlik TM, Raut CP, Rodriguez-Bigas MA. Colorectal carcinogenesis: MSI-H versus MSI-L. Dis Markers. 2004;20(4\u20135):199\u2013206.","journal-title":"Dis Markers"},{"issue":"4","key":"1493_CR47","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/jnci\/djh034","volume":"96","author":"A Umar","year":"2004","unstructured":"Umar A, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"1493_CR48","first-page":"1101","volume":"12","author":"Y Luo","year":"2019","unstructured":"Luo Y, et al. Relationship between CpG island methylation phenotype, microsatellite instability phenotype and mutation of KRAS, NRAS, and BRAF genes in colorectal cancer. Int J Clin Exp Pathol. 2019;12(3):1101\u20137.","journal-title":"Int J Clin Exp Pathol"},{"issue":"31","key":"1493_CR49","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.2217\/fon-2021-0552","volume":"17","author":"R Park","year":"2021","unstructured":"Park R, et al. The prognostic and predictive impact of BRAF mutations in deficient mismatch repair\/microsatellite instability-high colorectal cancer: systematic review\/meta-analysis. Future Oncol. 2021;17(31):4221\u201331.","journal-title":"Future Oncol"},{"issue":"12","key":"1493_CR50","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1038\/bjc.2015.160","volume":"112","author":"TT Seppala","year":"2015","unstructured":"Seppala TT, et al. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br J Cancer. 2015;112(12):1966\u201375.","journal-title":"Br J Cancer"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01493-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01493-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01493-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:03:08Z","timestamp":1779274988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01493-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1493"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01493-z","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was exempt from Institutional Review Board review because the NCDB contains no patient identifiers and does not involve direct interaction with human subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}